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CD1d-restricted Va14-Ja281 invariant abTCR1 (NKT) cells are well defined in the C57BL/6 mouse strain, but they remain
poorly characterized in non-NK1.1-expressing strains. Surrogate markers for NKT cells such as abTCR1CD42CD82 and
DX51CD31 have been used in many studies, although their effectiveness in defining this lineage remains to be verified. Here, we
compare NKT cells among C57BL/6, NK1.1-congenic BALB/c, and NK1.1-congenic nonobese diabetic mice. NKT cells were
identified and compared using a range of approaches: NK1.1 expression, surrogate phenotypes used in previous studies, labeling
with CD1d/a-galactosylceramide tetramers, and cytokine production. Our results demonstrate that NKT cells and their CD4/
CD8-defined subsets are present in all three strains, and confirm that nonobese diabetic mice have a numerical and functional
deficiency in these cells. We also highlight the hazards of using surrogate phenotypes, none of which accurately identify NKT cells,
and one in particular (DX51CD31) actually excludes these cells. Finally, our results support the concept that NK1.1 expression
may not be an ideal marker for CD1d-restricted NKT cells, many of which are NK1.1-negative, especially within the CD41 subset
and particularly in NK1.1-congenic BALB/c mice. The Journal of Immunology, 2001, 167: 1164–1173.
T he CD1d-restricted Va14-Ja281 invariant abTCR1(NKT)3 cells represent a T cell lineage that appears to beimportant in a diversity of immune responses ranging
from suppression of autoimmune disease to tumor rejection (re-
viewed in Ref. 1). These cells have been most extensively studied
in the C57BL/6 strain due to its allelic expression of NK1.1,
which, in conjunction with the abTCR, is used most frequently in
the identification of NKT cells. Most other common laboratory
mouse strains (for example BALB/c, CBA, C3H, 129, and nono-
bese diabetic (NOD)) do not express NK1.1. The reason for this
strain-dependent expression of NK1.1 is not known but may be
due to a strain-specific transacting factor (2). Until recently, the
investigation of NKT cells in non-NK1.1-expressing strains has
been hampered by the lack of an alternate marker, although
“NKT-like” cells appear to be present. Several surrogate pheno-
types have been used to represent NKT cells, for example,
CD62L2CD2423G112(3), CD41CD44high (4), abTCR1CD42
CD82(ab1DN) (5), Ly49a1CD1221CD31 (6), and DX51CD31
(7). However, it is not clear how accurately these phenotypes iden-
tify NKT cells, especially in NK1.1-negative strains.
NK1.1 has traditionally been used in the identification of NKT
cells, although the use of this marker is complicated by the exis-
tence of CD1d-dependent and -independent populations of
NK1.11 T cells (8, 9). The CD1d-dependent subset encompasses
the cells expressing the invariant Va14-Ja281 and biased Vb rep-
ertoire (8–10), and rapid IL-4-producing potential (10–13). CD1d-
independent NK1.11 T cells represent a separate lineage, the func-
tional relevance of which is unknown. In this paper, the term
“NKT cells” refers to the CD1d-dependent population. Another
reagent, tetrameric complexes of CD1d and a-galactosylceramide
(a-GalCer), has recently been developed to aid in the identification
of NKT cells. These complexes have been shown to bind stably
and selectively to NKT cells expressing the invariant Va14-Ja281
TCR a-chain in mice or Va24-JaQ TCR in humans, and tetramer-
labeled cells were not observed in TCR Ja2812/2 and CD1d2/2
mice (14, 15). CD1d/a-GalCer tetramers are advantageous in that
they detect NKT cells regardless of NK1.1 expression; however,
this reagent is limited by the possibility that some CD1d-restricted
NKT cells may not react with the a-GalCer glycolipid Ag. Here,
a combination of both approaches, labeling with anti-NK1.1 as
well as CD1d/a-GalCer tetramers, was used in the investigation of
NKT cells.
In this study, we have directly compared NKT cells among
C57BL/6, BALB/c, and NOD mice. These strains were selected as
they are believed to vary widely in their proportions of NKT cells.
Using the ab1DN surrogate phenotype, NOD mice have previ-
ously been shown to be deficient in NKT cells, particularly in the
thymus (3, 5, 16). In contrast, BALB/c mice have a high propor-
tion of ab1DN thymocytes and represent a prototypic Th2 re-
sponder strain. As NKT cells have been shown to be responsible
for the majority of IL-4 produced following thymocyte stimulation
(17–19), it was important to determine whether there was a rela-
tionship between variations in NKT cells and functional differ-
ences between these strains. NK1.1-congenic lines of BALB/c and
NOD mice (BALB.B6.-Cmv1r (BALB.NK1.1) and NOD.b-
Nkrp1b (NOD.NK1.1), respectively) were used to enable NK1.1
labeling of NKT cells. The development of these congenic mice
and CD1d/a-GalCer tetramers has allowed us to directly compare
the number of NKT cells and their CD4/CD8-defined subsets, their
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functional capacity in the form of IL-4/IFN-g production, and to
determine the effectiveness of some commonly used surrogate phe-
notypes on each of these backgrounds.
Materials and Methods
Mice
NK1.1-congenic BALB/c (BALB.NK1.1) (20) and NOD/Lt mice
(NOD.NK1.1) (21) were produced by introducing a segment of chromo-
some 6 containing the NK cell gene complex (22) from C57BL/6J mice
onto the BALB/c and NOD/Lt genetic backgrounds, respectively. A min-
imum of 10 backcrosses were conducted before using these mice. All mice
were purchased from the Animal Resources Center (Canning Vale, WA)
and housed either under standard conditions in the absence of specific
pathogens in the Centenary Institute Animal House (Newtown, New South
Wales, Australia) or for 1–2 wk in microisolators in the Monash University
Medical School Animal House (Prahran, Victoria, Australia). Mice were
used between 6 and 10 wk of age, and were age-matched within each
experiment.
Cell suspensions
Cell suspensions of thymus, spleen, bone marrow, and peripheral lymph
nodes (PLNs) were prepared as previously described (10). Hepatic leuko-
cytes were isolated by cutting individual livers into small pieces and gently
pressing through 200-gauge wire mesh. The cells were washed twice in
ice-cold PBS with 2% FCS and 0.02% azide and spun through 33.8%
Percoll (Amersham Pharmacia Biotech, Castle Hill, New South Wales,
Australia) for 12 min at 693 3 g. Recovered leukocytes were washed and
treated with red cell removal buffer (Sigma, Castle Hill, New South Wales,
Australia).
Purification of NKT cells
To enrich for thymic NKT cells, CD24(HSA)1 and CD81 thymocytes
were depleted by incubation with rat anti-mouse CD24 (clone J11D) and
rat anti-mouse CD8 (clone 3.155), respectively, followed by rabbit com-
plement (C-six Diagnostics, Germantown, WI). Splenic NKT cells were
enriched by incubation with anti-B220 (clone RA3.6B2), anti-CD24 (clone
M1/69), and anti-CD62L (clone MEL-14), followed by incubation with
anti-rat Ig magnetic beads (Dynal, Carlton, VIC, Australia) and depletion
using a magnetic cell separator. Enriched NKT cells were then surface-
labeled for flow cytometric sorting.
Flow cytometry
The following mAbs were used in multiparameter flow cytometric analy-
sis: anti-abTCR-allophycocyanin (clone H57-597), anti-CD4-FITC or
-CD4-PerCP (clone RM4-5), anti-CD8-biotin or -CD8-PerCP (clone 53-
6.7), anti-CD122-biotin (clone TMb-1), anti-NK1.1-PE (clone PK136,
mouse IgG2a), anti-DX5-FITC (clone DX5), anti-3G11 disialoganglioside
Ag-biotin (clone SM3G11) (all purchased from PharMingen, San Diego,
CA), anti-CD4-TRI-COLOR (clone CT-CD4), and anti-CD8-TRI-COLOR
(clone CT-CD8a) (Caltag Laboratories, Burlingame, CA). Biotinylated
mAbs were detected with streptavidin-Alexa Fluor 488 (Molecular Probes,
Eugene, OR) or streptavidin-PerCP (PharMingen). Culture supernatants of
anti-CD8 (clone 3.155), anti-CD24 (clone M1/69), and anti-CD62L (clone
MEL-14) (all grown in-house), and anti-Ly49A (clone YEI-32; a gift of M.
Smyth, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia)
were revealed with anti-rat IgG-FITC (Vector Laboratories, Burlingame,
CA). To prevent any cross-reactive binding of subsequent mAb to the
anti-rat IgG, cells were incubated with normal rat serum after this step.
Mouse anti-rat CD44 (clone OX-49, mouse IgG2a) was used as an isotype
control for anti-NK1.1. FcR block (anti-CD16/CD32, clone 2.4G2 culture
supernatant) was used routinely, except in cases where anti-rat IgG-FITC
was being used. PE-labeled, a-GalCer-loaded or unloaded (control)
mCD1d tetramers were a gift from O. Naidenko and M. Kronenberg (Di-
vision of Developmental Immunology, La Jolla Institute of Allergy and
Immunology, San Diego, CA), and their generation has been described
previously (15). Three- and four-color analysis, as well as multicolor sort-
ing, were performed using a FACSCalibur or FACStarPlus (BD Bio-
sciences, San Jose, CA). Sorted populations were usually .95% pure.
CellQuest software (BD Biosciences) was used for analysis.
In vitro T cell stimulation
Cells were stimulated by culturing in anti-CD3-coated microtiter plates
(either KT3-1.1, grown and purified in-house, or 145-2C11, PharMingen).
In most cases, cells were cultured at a density of 1 3 105 cells in 100 ml
tissue culture medium. In some cases 0.5 3 105 cells were cultured per
well; in these instances, the same number of NKT cells from each strain
was stimulated for direct comparison between the level of cytokines pro-
duced. Supernatants were harvested at 18–20 h, and analyzed for cytokine
production by ELISA. Cytokine readouts for samples with 0.5 3 105 cells
were adjusted to cytokines produced per 105 cells.
Cytokine assays
IL-4 and IFN-g were detected by sandwich ELISA as described previously
(10). Generally the limit of detection for IL-4 was 2 U/ml, and for IFN-g
0.1 ng/ml. Samples with undetectable cytokine levels were assigned the
lowest detectable value.
Statistical analysis
Quantitative differences between two samples were compared with the
Mann-Whitney U (rank sum) test. When three groups were being com-
pared, an ANOVA was performed followed by a Tukey post hoc analysis
to determine which mouse strain was different. When the data were found
not to be normally distributed, or the sample size was small, a Kruskal-
Wallis test was used, followed by Dunn’s post hoc test.
Results
NK1.11 T cells: frequency and tissue distribution
NK1.11 T cells were clearly present in each strain tested
(C57BL/6, NOD.NK1.1, and BALB.NK1.1 mice) and followed a
similar tissue-specific distribution in each strain (Fig. 1, Table I).
However, there were clear differences between strains in the pro-
portions of NK1.11 T cells present in each organ. In the thymus,
NOD.NK1.1 mice had considerably fewer NK1.11 T cells than
C57BL/6 and BALB.NK1.1 in terms of both their proportion and
FIGURE 1. NK1.11 T cell distribution. Cell suspensions from each tis-
sue were labeled with mAb specific for abTCR and NK1.1. Each density
plot shows NK1.1 vs abTCR expression by lymphoid-gated cells. The
proportion of lymphoid-gated cells in each quadrant is given in the top
right corner of each density plot. Each column represents a sample from the
mouse strain indicated. These data are representative of between 5 and 32
tests as detailed in Table I.
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number. This was predicted based on our previous results (5, 16,
23) where NOD mice were shown to have the lowest proportion of
ab1DN thymocytes compared with eight other strains tested.
However, BALB.NK1.1 mice also had one-third fewer thymic
NK1.11 T cells than C57BL/6 mice. This was surprising because
BALB/c has the highest proportion of ab1DN thymocytes (5).
Interestingly, the phenotype of NK1.11 T cells in BALB.NK1.1
thymus differed from that of C57BL/6 and NOD.NK1.1 in that
most had a lower level of NK1.1 expression and a higher level of
abTCR (Fig. 1).
In peripheral organs, the proportion and number of NK1.11 T
cells in both BALB.NK1.1 and NOD.NK1.1 mice were generally
reduced compared with C57BL/6. Here, the difference between
BALB.NK1.1 and C57BL/6 mice was more pronounced than in
the thymus, such that the proportions of NK1.11 T cells in
BALB.NK1.1 mice were similar to and, in some cases, lower than
in NOD.NK1.1 mice. For example, in the spleen, NOD.NK1.1 and
BALB.NK1.1 mice had a mean proportion of 0.4 and 0.5%
NK1.11 T cells respectively, compared with 1.2% in C57BL/6.
NK1.11 T cells represented 23% of T cells in the bone marrow of
C57BL/6 mice, and were again present in reduced proportions in
NOD.NK1.1 and BALB.NK1.1 mice, with BALB.NK1.1 mice
having the least. In the liver, NK1.11 T cells were found in the
highest proportions in C57BL/6 (20%), then NOD.NK1.1 mice
(16%), then BALB.NK1.1 mice (11%). Very few NK1.11 T cells
were detected in the PLNs of C57BL/6 mice, and the proportion
was even lower in NOD.NK1.1 and BALB.NK1.1 mice (Table I).
In addition to the variation in NK1.11 T cell numbers between
strains, some differences were detected in the proportions of
NK1.11abTCR2 and NK1.12abTCR1 cells (Fig. 1, Table I).
However, the most consistent difference noted between the strains
was the reduction of peripheral NK1.11 T cells in NOD.NK1.1
and BALB.NK1.1 mice in comparison to C57BL/6 mice such that
the proportion of NK1.11 T cells among total T cells was always
highest in this strain.
Tissue distribution of NK1.11 T cell subsets
Given that the proportion of NK1.11 T cells varied among the
three strains under investigation, and that three distinct subpopu-
lations of these cells exist (CD41CD82 (CD41), CD42CD82
(double negative, DN), and CD42CD81 (CD81)) (8–10), we
sought to determine whether the differences in NK1.11 T cells
applied to all of these subsets.
CD41 and DN subsets of NK1.11 T cells were found in the
thymus of all strains (Fig. 2). However, in contrast to C57BL/6
where the CD41 subset is in the majority in the thymus, the DN
population was increasingly prominent in NOD.NK1.1 and
BALB.NK1.1 mice, respectively. When the total number of each
subset was determined, the CD41 subset was found to be lower in
BALB.NK1.1 mice, whereas the number of both subsets of thymic
NK1.11 T cells were reduced in NOD.NK1.1 mice in comparison
to C57BL/6 mice (data not shown).
In the periphery, the proportion of each CD4/CD8-defined sub-
set within the NK1.11 T cell population was usually similar be-
tween C57BL/6 and BALB.NK1.1 mice. However, the proportion
of NK1.11 T cells that were CD41 was usually lower in
NOD.NK1.1 mice than in the other strains (Fig. 2). This reduction
did not account for the overall deficiency of peripheral NK1.11 T
cells in NOD.NK1.1 mice, as the number of DN NK1.11 T cells
was also decreased when compared with C57BL/6 mice. The
CD81 subset comprised a minor proportion of NK1.11 T cells in
the peripheral organs of each mouse strain, although these cells
were more abundant in the bone marrow and PLNs of C57BL/6
mice. Taken together, these results indicate that the NK1.11 T cell
population as a whole varied between strains.
Cytokine production by NK1.11 T cells
A key feature of NKT cells is their ability to rapidly produce cy-
tokines on primary stimulation. This functional characteristic was
investigated and compared in each strain. In the first series of
experiments, cytokine production by NK1.11 T cells was com-
pared between C57BL/6 and BALB.NK1.1 mice (Table II).
NK1.11 T cells isolated from the thymuses of these mice produced
high levels of IL-4 after 1 day of anti-CD3 stimulation. The level
of IL-4 produced by splenic NK1.11 T cells was also similar be-
tween these two strains and, as previously reported for C57BL/6
mice (10), this level was lower than that produced by thymic
NK1.11 T cells. IFN-g was also produced by NK1.11 T cells
Table I. Tissue distribution of NK1.11 T cellsa
Organ Strain nb
Total Cell No.
(31026)
% NK1.11abTCR1
(NK1.11T)
% NK1.11abTCR2
(NK)
% NK1.12abTCR1
(NK1.12 T)
% T Cells That
Express NK1.1
Thymusc C57BL/6 31 200 6 50d 0.45 6 0.15 0.05 6 0.02
NOD.NK1.1 17 145 6 40 0.16 6 0.07*† 0.10 6 0.03*†
BALB.NK1.1 25 230 6 90 0.3 6 0.1*† 0.04 6 0.02†
Spleen C57BL/6 32 110 6 20 1.2 6 0.5 2.5 6 0.7 24 6 3 5 6 2
NOD.NK1.1 20 90 6 25 0.4 6 0.1* 2.2 6 0.5† 36 6 5*† 1.1 6 0.2*
BALB.NK1.1 25 130 6 30 0.5 6 0.1* 3.9 6 0.7*† 27 6 4*† 1.7 6 0.4*
Bone marrow C57BL/6 24 15 6 4 0.6 6 0.2 1.1 6 0.4 2 6 1 23 6 6
NOD.NK1.1 10 12 6 3 0.3 6 0.1*† 3.2 6 0.6*† 4 6 2*† 8 6 4*
BALB.NK1.1 19 12 6 3 0.11 6 0.05*† 1.0 6 0.4† 1.0 6 0.6*† 11 6 4*
Liver C57BL/6 20 3 6 1 20 6 6 9 6 3 27 6 6 40 6 10
NOD.NK1.1 10 1.1 6 0.5 16 6 3*† 14 6 3* 35 6 6* 32 6 6*
BALB.NK1.1 21 4 6 2 11 6 3*† 15 6 3* 38 6 6* 22 6 5*
PLN C57BL/6 5 26 6 3 0.39 6 0.05 0.8 6 0.1 52 6 2 0.74 6 0.08
NOD.NK1.1 5 26 6 3 0.13 6 0.02* 0.39 6 0.09* 74 6 2* 0.18 6 0.03*
BALB.NK1.1 5 31 6 5 0.13 6 0.01* 0.57 6 0.09 70 6 1 0.18 6 0.02*
a Cells were labeled with mAb specific for abTCR and NK1.1. Populations were defined based on the quadrants shown in Fig. 1. *, Significantly different from C57BL/6
( p # 0.05); †, significant difference obtained between NOD.NK1.1 and BALB.NK1.1 strains ( p # 0.05).
b n, No. of samples tested.
c The percentage of NK1.12abTCR1 cells was not determined as most thymocytes are immature T cells.
d Results represent mean 6 SD for the number of samples indicated, from a minimum of three individual experiments.
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following stimulation, although the amount varied between strains,
and again, less was produced by splenic NK1.11 T cells than by
thymic NK1.11 T cells.
In a separate series of experiments, IL-4 and IFN-g production
by NK1.11 T cells was compared between C57BL/6 and
NOD.NK1.1 mice. Thymic NKT cells from NOD.NK1.1 mice
produced significantly less IL-4 after 1 day of stimulation, com-
pared with NK1.11 T cells from C57BL/6 mice (Table III). In
contrast, the level of IFN-g produced by thymic NK1.11 T cells
was similar between these strains. IL-4 production by NOD.NK1.1
NK1.11 T cells from the spleen was also approximately half that
of C57BL/6 mice. In this series of experiments, cytokine secretion
was also measured after 2 days of stimulation, by which time the
level of IL-4 produced by NK1.11 T cells from the thymus and
spleen of NOD.NK1.1 mice had increased and was comparable to
C57BL/6 mice (data not shown). The amount of cytokines pro-
duced by NK1.11 T cells isolated from C57BL/6 mice varied be-
tween these two sets of experiments so that cytokine production by
these cells from NOD.NK1.1 and BALB.NK1.1 mice cannot be
directly compared. This variation was potentially caused by the use
of different anti-CD3 clones for stimulation; in the first series clone
KT3 (rat anti-mouse CD3) while in the second series the clone
145-2C11 (hamster anti-mouse-CD3; PharMingen) was used, and
we have found the latter reagent to be more effective for cell stim-
ulation (K. J. L. Hammond and D. I. Godfrey, unpublished
observation).
Unlike C57BL/6 and NOD.NK1.1 mice, NK1.1-negative T cells
from the thymus and spleen of BALB.NK1.1 mice also produced
IL-4 and IFN-g following 1 day of anti-CD3 stimulation (Table II).
Although these NK1.1-negative cytokine-producing T cells were
not fully characterized, in the thymus they resided within a
CD41CD82CD242 phenotype (data not shown).
Strain comparison of CD1d/a-GalCer tetramer binding cells
NK1.1 is the most commonly used marker of NKT cells, particu-
larly in C57BL/6 mice; however, there is evidence indicating that
NK1.1-negative T cells exist that appear to have very similar char-
acteristics to NKT cells. These have been described in C57BL/6
mice (14, 15, 24), but not in other strains. CD1d/a-GalCer tetram-
ers represent an extremely useful reagent because their labeling is
dependent on the specific interaction between the restricted TCR
and unique ligand (CD1d/a-GalCer) of NKT cells, thereby iden-
tifying NKT cells regardless of NK1.1 expression. Thus, we have
compared CD1d/a-GalCer tetramer1 T cells to NK1.11 T cells in
each of the three strains under investigation. CD1d tetramer that
had not been loaded with a-GalCer was always used as a negative
control (Fig. 3A).
The total proportion of CD1d/a-GalCer tetramer-binding T cells
is presented in Fig. 3A and Table IV. Surprisingly, in contrast to
the results obtained using the NK1.1 marker, the frequency of
CD1d-restricted NKT cells was very similar between
BALB.NK1.1 and C57BL/6 mice in each organ investigated. Con-
sistent with the data using NK1.1, NOD.NK1.1 mice had fewer
thymic CD1d/a-GalCer tetramer1 T cells than the other strains,
and also had the lowest proportion in the spleen and liver. The
proportion of CD1d/a-GalCer tetramer1 T cells in the bone mar-
row of NOD.NK1.1 mice was lower than in C57BL/6 mice but not
different from BALB.NK1.1. The thymus and spleen of
BALB.NK1.1 mice contained 3- to 4-fold more CD1d/a-GalCer
tetramer1 T cells than NKT cells (Table IV). In concordance with
the data using NK1.1 (Fig. 1), the expression of abTCR by CD1d/
Table II. Cytokine production by NK1.11 T cells from C57BL/6 and BALB.NK1.1 micea
Organ Strain
IL-4 (U/ml) IFN-g (ng/ml)
nb NK1.11 T n NK1.12 T n NK1.11 T n NK1.12 T
Thymus C57BL/6 22 600 6 100c 22 16 6 4 15 4.8 6 0.5 15 0.1 6 0.0
BALB.NK1.1 21 700 6 200 22 900 6 250* 14 1.3 6 0.2* 15 0.9 6 0.2*
Spleen C57BL/6 12 130 6 50 17 13 6 3 8 0.2 6 0.0 13 0.1 6 0.0
BALB.NK1.1 12 200 6 90 18 36 6 9† 8 0.8 6 0.2† 13 0.1 6 0.0
a Supernatant was harvested from FACS-sorted NK1.11abTCR1 cells and NK1.12abTCR1 cells after stimulation for 18–20 h on anti-CD3-coated microtiter plates. IL-4
and IFN-g were then measured in supernatants by ELISA. Cells were cultured at a density of 1 3 106 cells/ml.
b n, No. of replicate culture samples tested.
c Results represent mean 6 SE for the number of samples indicated, from two to eight individual experiments. T, abTCR1 cells; *, p # 0.0005; †, p # 0.05 (Mann-Whitney
U rank sum test).
FIGURE 2. Tissue distribution of CD4/CD8-defined NK1.11 T cell
subsets. Cell suspensions from each tissue were labeled with mAb specific
for abTCR, NK1.1, CD4, and CD8. Each dot plot shows CD4 vs CD8
expression by electronically gated NK1.11 T cells that were enriched by
acquisition gating. The proportion of gated cells in each quadrant is given
in the top right corner of each dot plot. Each column represents a sample
from the mouse strain indicated. These data are representative of between
5 and 32 tests as detailed in Table I.
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a-GalCer tetramer1 T cells in the thymus, and to a lesser extent,
the spleen of BALB.NK1.1 mice, ranged from intermediate to high
levels, similar to the level of expression by conventional T cells
(Fig. 3A). Non-NK1.1-congenic NOD/Lt and BALB/c mice were
also investigated, and no differences were detected in the propor-
tions of CD1d/a-GalCer tetramer1 T cells between these strains
and the corresponding NK1.1-congenic strain in any organ tested
(Table V). The level of abTCR expression by CD1d/a-GalCer
tetramer1 thymocytes in BALB/c mice was also very similar to
that of BALB.NK1.1 mice (data not shown).
Upon examination of abTCR1 cells colabeled for NK1.1 and
CD1d/a-GalCer tetramer, the reason for the discrepancy between
the proportions of cells labeled with these two markers became
clear. In C57BL/6 mice, most CD1d/a-GalCer tetramer-binding T
cells also expressed NK1.1 (Fig. 4). In line with previous reports
(14, 15), NK1.1-negative CD1d/a-GalCer tetramer-binding T cells
were also identified in this strain, and comprised a minority of
CD1d/a-GalCer tetramer1 T cells in most organs (Fig. 4, Table
VI). In NOD.NK1.1 mice, the fraction of NK1.1-negative cells
among CD1d/a-GalCer tetramer1 T cells was larger; the propor-
tion ranged from 17% in the liver to 45% in the thymus and bone
marrow, and 65% in the spleen. In BALB.NK1.1 mice, the ma-
jority (70–75%) of CD1d/a-GalCer tetramer1 NKT cells were
NK1.1-negative in the thymus and spleen of this strain; this pop-
ulation comprised nearly half of the CD1d/a-GalCer tetramer1
NKT cells in the bone marrow and liver. Furthermore, these cells
were predominantly CD41 (Fig. 3B). When considering CD1d/a-
GalCer tetramer1 T cells, the ratio of CD41 and CD42 cells was
similar in the thymus of each strain; however, there were some
small variations in the proportions of these subsets in other tissues.
FIGURE 3. CD1d/a-GalCer tetramer vs abTCR expression (A) and CD4 vs NK1.1 expression on CD1d/a-GalCer tetramer1 abTCR1 cells (B). Cell
suspensions from each tissue were labeled with CD1d/a-GalCer tetramer and mAb specific for abTCR, NK1.1, and CD4. A, Each density plot shows
CD1d/a-GalCer tetramer vs abTCR expression by lymphoid-gated cells. The first column shows control tetramer labeling (CD1d/vehicle tetramer) vs
abTCR on C57BL/6. Similar controls were conducted on the other two strains (data not shown). The number represents the proportion of lymphoid-gated
cells within the region indicated. B, Density plots show CD4 vs NK1.1 expression by abTCR1 CD1d/a-GalCer tetramer1 cells, gated as shown in A. The
proportion of gated cells in each quadrant is given in the top right corner of each density plot. Each column represents a sample from the mouse strain
indicated. These data are representative of nine separate mice.
Table III. Cytokine production by NK1.11 T cells from C57BL/6 and NOD.NK1.1 micea
Organ Strain
IL-4 (U/ml) IFN-g (ng/ml)
nb NK1.11 T n NK1.12 T n NK1.11 T n NK1.12 T
Thymus C57BL/6 9 1200 6 100c 6 15 6 4 9 7 6 1 6 0.1 6 0.0
NOD.NK1.1 7 380 6 90* 6 5 6 1 6 10 6 2 6 0.1 6 0.0
Spleen C57BL/6 6 560 6 80 6 7 6 1 6 0.3 6 0.1 6 1.2 6 0.3
NOD.NK1.1 6 240 6 20* 6 7 6 1 6 1.0 6 0.3† 6 0.7 6 0.1
a Supernatant was harvested from FACS-sorted NK1.11abTCR1 cells and NK1.12abTCR1 cells after stimulation for 18–20 h on anti-CD3-coated microtiter plates. IL-4
and IFN-g were then measured in supernatants by ELISA. Cells were cultured at a density of 1 3 106 cells/ml.
b n, No. of replicate culture samples tested.
c Results represent mean 6 SE for the number of samples indicated, from two to eight individual experiments. T, abTCR1 cells; *, p # 0.005; †, p # 0.05 (Mann-Whitney
U rank sum test).
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For example, BALB.NK1.1 mice had the highest proportion of
CD41 CD1d/a-GalCer tetramer1 T cells in the spleen (Fig. 3B).
A population of NK1.11 T cells was also identified in all strains
that did not bind the CD1d/a-GalCer tetramer (Fig. 4, Table VI).
These cells represented a greater proportion of NKT cells in the
spleen and the bone marrow of all strains, and were higher in
NOD.NK1.1 mice.
Assessment of surrogate phenotypes for CD1d-restricted NKT
cells
Due to the absence of NK1.1 expression in most mouse strains,
many studies have relied on other markers, or combinations
thereof, in an attempt to identify NKT cells in mice other than
C57BL/6. However, it is not clear how well these surrogate phe-
notypes distinguish NKT cells, particularly in NK1.1-negative
strains such as BALB/c and NOD where they have most com-
monly been used. Here, we have compared the cells identified with
surrogate markers to NK1.11 and CD1d/a-GalCer tetramer1 T
cells in the three strains under investigation.
CD82CD242CD62L23G112 T cells. NOD mice were reported
to have a numerical and functional deficiency in NKT cells based
on the lower proportion of abTCR1CD62L23G112 cells found
among CD42CD82CD242 thymocytes in this strain (3). Also,
IL-4 production by CD82CD242 thymocytes from NOD mice fol-
lowing stimulation was lower than the corresponding cells isolated
from C57BL/6, BALB/c, C3H/He, and DBA/2 mice. We found
that this phenotype was one of the most reliable for distinguishing
NKT cells, particularly in the liver, and to a lesser extent in the
thymus (Fig. 5A, Table VII). However, in the spleen, few T cells
with this phenotype expressed NK1.1, and the proportion that was
CD1d/a-GalCer tetramer1 was lower and varied between strains.
Furthermore, as NKT cells appear to express low to intermediate
levels of these surface markers (dashed line in Fig. 5A), a signif-
icant fraction of them may be excluded by this phenotype.
CD3/abTCR1CD1221Ly49A1 T cells. This surface marker
phenotype has been used to identify and purify NKT cells from
FIGURE 4. Comparison of CD1d/a-GalCer tetramer vs NK1.1 expres-
sion on T cells. Cell suspensions from each tissue were labeled with CD1d/
a-GalCer tetramer and mAb specific for abTCR and NK1.1. Each density
plot shows CD1d/a-GalCer tetramer vs NK1.1 expression by lymphoid-
gated abTCR1 cells. Each column represents a sample from the mouse
strain indicated. These data are representative of nine separate mice.
Table V. Proportion of CD1d/a-GalCer1 T cells in NK1.1-congenic
and noncongenic BALB/c and NOD/Lt strainsa
Strain nb
Organ
Thymus Spleen Liver
C57BL/6 9 0.6 6 0.2c 1.1 6 0.2 27 6 5
NOD.NK1.1 9 0.16 6 0.05 0.6 6 0.2 18 6 4
NOD/Lt 4 0.15 6 0.1 0.58 6 0.03 18 6 3
BALB.NK1.1 9 0.8 6 0.3 1.4 6 0.1 26 6 4
BALB/c 4 0.74 6 0.04 1.3 6 0.2 22 6 5
a Cells were labeled with mAb specific for abTCR and CD1d/a-GalCer tetramer.
Regions were set as shown in Fig. 3A.
b n, No. of samples tested.
c Results represent mean 6 SD for the number of samples indicated, from a
minimum of two individual experiments. CD1d/a-GC, CD1d/a-GalCer tetramer.
Table IV. Comparison of NK1.11 and CD1d/a-GalCer1 T cell proportionsa
Organ Strain
Total Cell No.
(31026)
% Total CD1d/a-GC1
abTCR1 Cells
% Total NK1.11
abTCR1 Cells
Ratio CD1d/a-GC1:
NK1.11abTCR1 Cells
Thymus C57BL/6 190 6 30b 0.6 6 0.2 0.6 6 0.24 1.1 6 0.1
NOD.NK1.1 170 6 40 0.16 6 0.05*† 0.16 6 0.04*† 1.1 6 0.2†
BALB.NK1.1 170 6 50 0.8 6 0.3† 0.3 6 0.2† 3 6 1*†
Spleen C57BL/6 100 6 10 1.1 6 0.2 0.9 6 0.2 1.2 6 0.1
NOD.NK1.1 100 6 30 0.6 6 0.2*† 0.36 6 0.05* 1.7 6 0.5†
BALB.NK1.1 130 6 30 1.4 6 0.1† 0.35 6 0.08* 4 6 0.8*†
Bone marrow C57BL/6 11 6 2 0.40 6 0.08 0.7 6 0.1 0.6 6 0.0
NOD.NK1.1 10 6 2 0.13 6 0.05* 0.26 6 0.05 0.5 6 0.1†
BALB.NK1.1 10 6 1 0.2 6 0.1 0.17 6 0.08* 1.3 6 0.1†
Liver C57BL/6 1.9 6 0.5 27 6 5 26 6 5 1.0 6 0.2
NOD.NK1.1 1.8 6 0.8 18 6 4*† 21 6 4 0.9 6 0.1†
BALB.NK1.1 2 6 1 26 6 4† 17 6 4* 1.6 6 0.3†
a Cells were labeled with mAb specific for abTCR, NK1.1, and CD1d/a-GalCer tetramer. Regions were set as shown in Fig. 3A.
b Results represent mean 6 SD for nine mice of each strain, from five individual experiments, except for the bone marrow data, which are derived from five mice from three
experiments. CD1d/a-GC, CD1d/a-GalCer tetramer; *, Significantly different from C57BL/6 ( p # 0.05); †, significant difference obtained between NOD.NK1.1 and
BALB.NK1.1 strains ( p # 0.05).
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NOD mice for adoptive transfer studies (6). However, when iso-
lated from the spleen of C57BL/6 mice, CD31CD1221Ly49A1 T
cells produced IFN-g but not IL-4 after anti-abTCR stimulation in
vitro (6). Examination of this phenotype in NK1.1-congenic
strains, or using CD1d/a-GalCer tetramers, indicates that although
it may highly enrich for a subset of NKT cells, these represent only
a small minority: 5–16% of the total NKT cell population (Fig. 5B,
Table VII). As the expression of Ly49A was found to be much
lower in BALB.NK1.1 mice (data not shown), this phenotype was
not appropriate for use in this strain.
CD3/abTCR1DX51. DX5 was first identified as a marker of NK
cells (25). Although several recent studies have used this marker to
identify NKT cells (7, 26), we and others have shown that most
NK1.11 T cells in C57BL/6 mice do not express DX5 (8, 10).
Here, we demonstrate that DX5 is not expressed by CD1d/a-
GalCer tetramer-binding NKT cells in any of the strains under
investigation (Fig. 5C, Table VII).
ab1DN cells. The ab1DN phenotype has been used, particu-
larly in the thymus, to represent NKT cells in strains where NK1.1
was not expressed (5, 27, 28). It is known that NKT cells represent
;30% of these cells in C57BL/6 mouse thymus (29). As we have
reported, the proportion of thymic DN cells that express the
abTCR varies among mouse strains, with BALB/c having the
highest, and NOD mice the lowest, among the strains tested (5).
Despite the variation in ab1DN thymocytes, the fraction that ex-
pressed NK1.1 was highly conserved between all three strains
(;30%); however, more ab1DN thymocytes in BALB.NK1.1
mice bound CD1d/a-GalCer tetramer (Table VII). In the periph-
ery, the proportion of ab1DN cells also differed between strains
(data not shown), as did the percentage that expressed NK1.1 or
bound CD1d/a-GalCer tetramer. In the liver, most ab1DN cells
were NKT cells; however, few splenic ab1DN cells were CD1d/
a-GalCer tetramer1. These results indicate that although the
ab1DN phenotype enriches for NKT cells in the thymus and liver,
it may be an overestimate of DN NKT cells, and obviously does
not account for CD41 NKT cells. Furthermore, this phenotype
cannot be used to accurately represent these cells in the periphery,
as the proportion that were NK1.11 or CD1d/a-GalCer tetramer1
was not conserved between organs or mouse strains.
FIGURE 5. Analysis of surrogate phenotypes. Cell suspensions were
labeled with CD1d/a-GalCer tetramer and mAb specific for 3G11, CD8,
CD24, CD62L, CD4, and abTCR (A); Ly49, CD122, and abTCR (B);
NK1.1, DX5, and abTCR (C); and CD4, CD8, and abTCR (D). The first
column shows the means by which the surrogate phenotypes were initially
isolated (by electronic gating). The second column shows the expression of
CD1d/a-GalCer tetramer (and NK1.1 in C) on cells with the surrogate
phenotype. The third column shows the surrogate markers on NKT cells
defined by CD1d/a-GalCer tetramer1 abTCR1 cells. This data are repre-
sentative of samples from the thymus (A, B, and D) or liver (C) of C57BL/6
mice. Similar analysis was conducted for the other two strains (data not
shown) as detailed in Table VII.
Table VI. NK1.1 vs CD1d/a-GalCer tetramer labeling of T cells between strainsa
Organ Strain
% abTCR1 Cells That
Express NK1.1
% abTCR1 Cells That
Bind CD1d/a-GC
% NK1.11 T Cells That
Do Not Bind CD1d/a-GC
% CD1d/a-GC1 T Cells That
Do Not Express NK1.1
Thymusb C57BL/6 3.6 6 0.8c 4.1 6 0.8 11 6 4 21 6 5
NOD.NK1.1 0.8 6 0.2*† 1.0 6 0.2*† 30 6 10* 45 6 8*
BALB.NK1.1 2 6 1 5 6 2† 18 6 3 70 6 10*
Spleen C57BL/6 5.6 6 0.9 5 6 1 34 6 3 24 6 5
NOD.NK1.1 2.4 6 0.9* 2.4 6 0.9*† 70 6 10*† 65 6 6*
BALB.NK1.1 2.6 6 0.7* 6 6 1† 41 6 6† 75 6 5*
Bone marrow C57BL/6 24 6 9 13 6 4 57 6 2 18 6 4
NOD.NK1.1 9 6 2* 4 6 1† 78 6 4† 46 6 2
BALB.NK1.1 18 6 6 21 6 10† 50 6 10† 51 6 4*
Liver C57BL/6 55 6 7 52 6 6 12 6 1 6 6 2
NOD.NK1.1 42 6 9 36 6 8*† 28 6 8*† 17 6 7*
BALB.NK1.1 32 6 9* 49 6 7† 10 6 2† 40 6 10*
a Cells were labeled with mAb specific for abTCR, NK1.1, and CD1d/a-GalCer tetramer. abTCR1 cells were electronically gated and analyzed for their expression of NK1.1
and CD1d/a-GalCer tetramer, as shown in Fig. 3B.
b abTCRhigh cells were analyzed in the thymus.
c Results represent mean 6 SD for nine mice of each strain, from five individual experiments, except for the bone marrow data, which are derived from five mice from three
experiments. CD1d/a-GC, CD1d/a-GalCer tetramer; *, Significantly different from C57BL/6 ( p # 0.05); †, significant difference obtained between NOD.NK1.1 and
BALB.NK1.1 strains ( p # 0.05).
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Discussion
NKT cells have a central role in immune responses ranging from
tumor rejection to the regulation of autoimmunity. Although they
are believed to be present in most strains of mice, the identification
of these cells in mice lacking NK1.1 expression has been difficult.
A range of surrogate phenotypes has been used in an attempt to
identify NKT cells in all strains of mice; however, the effective-
ness of these phenotypes in isolating these cells remains uncertain.
Thus, if we are to interpret studies of NKT cells in strains other
than C57BL/6 with confidence, it is important to verify the status
of NKT cells in these strains with reliable markers. The marker of
choice for NKT cells has traditionally been the NK1.1 molecule,
used in conjunction with abTCR, CD4, and CD8 labeling. The
generation of BALB/c and NOD mice congenic for the NK1.1
locus has made it possible to compare and contrast NK1.11 T cells
between these strains. NK1.11 T cells were indeed present in each
strain and, with the exception of NK1.11 T cells in BALB.NK1.1
thymus, the levels of cell surface expression of NK1.1 and abTCR
was similar in all three strains. NK1.11 T cells generally also had
a similar tissue distribution and TCR-Vb bias (data not shown),
and CD41, DN, and CD81 subsets of these cells were present in
each strain. However, significant interstrain differences in the pro-
portions of NK11.1 T cells were observed. As was predicted based
on earlier studies, NOD.NK1.1 mice had lower numbers of NKT
cells in the thymus than C57BL/6 and BALB.NK1.1 mice. Unex-
pectedly though, BALB.NK1.1 mice also had slightly fewer thy-
mic NKT cells than C57BL/6, and upon examination, both
BALB.NK1.1 and NOD.NK1.1 mice were found to have fewer
peripheral NK1.11 T cells than C57BL/6.
The explanation for the low proportion of thymic and peripheral
NK1.11 T cells in BALB.NK1.1 mice was revealed by experi-
ments in which these cells were colabeled with CD1d/a-GalCer
tetramer. In contrast to C57BL/6 and NOD.NK1.1 mice, most CD1d/
a-GalCer tetramer1 NKT cells were NK1.12 in this strain. These
cells have previously been identified in C57BL/6 mice (14, 15), and
were reported to be phenotypically similar to NK1.11 CD1d/a-
Gal-Cer tetramer1 cells (i.e., Vb8 biased, CD441CD691Ly6Chigh
CD1221) except that a high proportion expressed CD49d (a4 inte-
grin) homing receptor (14). Before the development of CD1d/a-Gal-
Cer tetramers, the possibility that NK1.1-negative NKT cells may be
present in C57BL/6 mice had been suggested by several investigators.
Among the NK1.1-negative CD41 T cell population in MHC class II
(I-A b-chain)-deficient mice, cells were identified that were TCR-
Vb8 biased, and expressed the invariant Va14-Ja281 chain (24, 30,
31). Furthermore, these NK1.1-negative CD41 T cells produced IL-4
and IFN-g in response to anti-CD3, -CD1, and -a-GalCer treatment in
vitro (24, 30). It was difficult to identify these cells in wild-type mice,
although NK1.1-negative CD441CD62L2CD41 T cells from
C57BL/6 mice were shown to produce IL-4 after anti-CD3 stimula-
tion (30, 31).
The reason for the absence of NK1.1 on some NKT cells, par-
ticularly in BALB.NK1.1 mice, is not known. This may be due to
the activation state of NKT cells in the BALB.NK1.1 background;
in contrast to C57BL/6 and NOD.NK1.1 mice, NKT cells of
BALB.NK1.1 mice (particularly those of the thymus and, to a
lesser extent, the spleen) expressed lower levels of NK1.1 and
higher levels of abTCR than the other strains. When NKT cells are
activated through CD3 or CD1 in vitro they have been shown to
down-regulate NK1.1 on the cell surface (32). This is not related
to the levels of CD1d expression, which we have found to be
similar among the three strains in question (data not shown).Ta
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A population of NK1.11 T cells that did not bind CD1d/a-
GalCer tetramer was also identified. These cells were more prom-
inent in organs such as the spleen and bone marrow, and were
usually highest in NOD.NK1.1 mice. They also included CD41,
DN, and CD81 cells (data not shown). These cells probably in-
clude the CD1d-independent NK1.11 T cells, described in detail
by several researchers (8–10). Unlike ‘classical’ NKT cells,
CD1d-independent NK1.11 T cells do not express a biased TCR
repertoire or secrete high levels of cytokines following stimulation,
and are mostly thymus independent. Some of these cells may be
conventional T cells as virus-specific T cells have been observed to
up-regulate NK cell markers, including NK1.1 (33, 34). However,
an alternate possibility that should be considered is that some
NK1.11 CD1d/a-GalCer tetramer-negative cells could be CD1d-
restricted but may express a diverse TCR and/or recognize ligands
other than a-GalCer. T cell hybridomas and T cell clones have
been produced that are reactive to CD1d but do not express the
canonical Va14-Ja281 rearrangement (35–37). These T cell
clones, which were DN or CD8aa1, produced large amounts of
IFN-g and IL-10 following stimulation with CD1d, and were also
cytotoxic against CD1d1 APC (36). CD1d/a-GalCer tetramers did
not bind CD1d-restricted T cell hybridomas that were Va142 (14,
15), prompting the suggestion that this may be due to the absence
of the specific (and unknown) ligand (15). The relationship of
these cells to invariant Va14-Ja281 TCR1 cells is unclear. A
functional analysis of CD1d/a-GalCer tetramer-negative NK1.11
T cells may help determine whether these are NKT cells, although
the results may be complicated if this population contains a mix-
ture of CD1d-independent and -dependent cells.
This study has reinforced two important limitations in the use of
the NK1.1 marker to identify NKT cells. One is that NK1.1 is not
expressed by all CD1d-restricted NKT cells (14, 15, 24). These
cells represented the vast majority of CD1d-restricted NKT cells in
BALB.NK1.1 mice, and were also a sizable population in
NOD.NK1.1 mice. The other is that some NK1.11 T cells exist
that may not be NKT cells (as defined by a biased TCR expression,
CD1d restriction, and high levels of cytokine production) (8–10).
Several studies have used NK1.1-congenic strains (BALB/c and
NOD) to identify NKT cells (38–40). Our data indicate that not
only may NK1.1 be an unreliable marker of these cells in some
organs of C57BL/6 mice, it may be a very poor marker of these
cells in other NK1.1-congenic strains. Therefore, CD1d/a-GalCer
tetramers are probably a more reliable means of identifying NKT
cells.
These results both verify and expand earlier observations (3, 5, 23,
39) that NOD mice appear to be both numerically and functionally
deficient in NKT cells. More importantly, this is the first study to
directly demonstrate a deficiency in peripheral NKT cells in NOD
mice. Gombert et al. (3) reported that Ly49A1CD3intIL2Rb1 cells
were reduced in the spleen of NOD mice compared with C57BL/6;
however, the meaning of this result was unclear as they also showed
that this phenotype did not correlate with NK1.11CD3intIL2Rb1
cells in C57BL/6 mice (3). Another study was published using
NK1.1-congenic NOD mice, but did not provide this information
(39). A very recent study by Carnaud et al. (41) described a line of
NK1.1-congenic NOD mice that exhibited enhanced cytokine pro-
duction (IL-4 and IFN-g) by NKT cells and a reduced incidence of dia-
betes. In contrast, the rate and incidence of diabetes in the NOD.NK1.1
mice studied here did not differ between heterozygous congenic mice and
the parental NOD/Lt strain, and thymic abTCR1DN NKT cells from
these congenic mice produced similar levels of IL-4 and IFN-g (as de-
tected by intracellular cytokine staining) to parental NOD/Lt mice (21).
Although the reasons for these differences are not clear, one possible
explanation is that the Carnaud line may carry contaminating background
genes that affect these phenotypes.
Very little is known about the status of CD41 and DN NKT
cells in strains other than C57BL/6. This information is relevant as
it was possible that interstrain variations in the NKT cell popula-
tion were related to a particular subset. Using NK1.1 as a marker,
similar proportions of each subset were present between C57BL/6
and BALB.NK1.1 mice, except for the thymus, where more
NK1.11 T cells were DN in NOD.NK1.1 and BALB.NK1.1 mice.
However, when CD1d/a-GalCer tetramer binding cells were ex-
amined, the ratio of CD41 to DN NKT cells was similar among the
three strains in this tissue. The proportion of CD81 NK1.11 T
cells varied among strains; however, these cells constitute a minor
population that does not bind CD1d/a-GalCer tetramer (data not
shown, and Refs. 14, 15) and are not generally considered to be
NKT cells. When combined, these data indicate that both NKT cell
subsets were reduced in the thymus and periphery of NOD.NK1.1
mice, whereas they are present in similar proportions in
BALB.NK1.1 and C57BL/6 mice.
NKT cells from C57BL/6 and BALB.NK1.1 mice were func-
tionally similar in terms of the level of IL-4 produced; however,
these cells isolated from both the thymus and spleen of
NOD.NK1.1 mice produced significantly less IL-4 than those from
C57BL/6 mice after 1 day of stimulation. This finding corresponds
with previous reports showing that NOD thymocytes and splenic T
cells produced much lower levels of IL-4 than the same cells iso-
lated from BALB/c mice (42). A deficiency in IL-4 production by
NOD NKT cells has also been implied in previous studies.
CD242CD82 thymocytes (enriched for NKT cells) from NOD
mice produced much less IL-4 following in vitro stimulation than
those from several other strains (3). Using intracellular cytokine
staining, fewer DN thymocytes from NOD mice were positive for
IL-4 than C57BL/6 after 6 h of stimulation (23), and IL-4 produc-
tion by NOD spleen cells following anti-CD3 treatment in vivo
was found to be very low (3). However, considering the differences
in the frequency of NKT cells between these strains, it was im-
portant to determine whether, on a per NKT cell basis, less IL-4
was produced. The fact that by day 2 NKT cells from both the
thymus and spleen of NOD.NK1.1 mice produced as much IL-4 as
those from C57BL/6 suggested that this functional deficiency is
limited to short-term stimulation. The other noteworthy difference
was that NK1.1-negative T cells from BALB.NK1.1 mice, partic-
ularly from thymus, were capable of rapid IL-4 production. The
higher frequency of CD1d/a-GalCer tetramer1 cells among
NK1.1-negative T cells in this strain may partly explain this result.
However, as these cells represent a minority of the total NK1.1-
negative T cell population, they would have to produce a larger
amount than their NK1.11 counterparts to account for all of the
IL-4 observed. Alternatively, conventional CD41 T cells in
BALB.NK1.1 mice may be capable of producing IL-4 after short-
term stimulation.
In summary, this is the first study to provide a detailed compar-
ison of CD1d-restricted NKT cells (and their subsets) in three
commonly used mouse strains. We also confirm that NOD mice
are numerically and functionally deficient in NKT cells in most
tissues when compared with C57BL/6 and BALB/c mice. Based
upon our investigation of surrogate phenotypes, it seems wise to
avoid using them, where possible, to represent NKT cells. More-
over, even NK1.1 can be an unreliable marker of these cells, par-
ticularly in BALB.NK1.1 mice. We suggest that CD1d/a-GalCer
tetramers are currently the most accurate marker of invariant TCR-
expressing NKT cells and offer the added advantage of identifying
these cells in strains other than C57BL/6.
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